Building Upon Core Technology
Technetx,
The market reaction was not all that bad as BLUD closed at 9 7/8 just 1/8th or -1.25% off its recent high of $10.00 on light volume of 35,300 shares.
This agreement with IBG Systems Limited only validates Immucor's conviction that the ABS2000 will be approved and drive the company's growth for the foreseeable future. It is comforting to know that this company has a vision and is willing to take the necessary steps ensuring success.
<<Edward L. Gallup, President of Immucor, Inc. commented, "This agreement expands our corporate vision to become the world leader in blood bank automation by offering a line of automated and semi-automated products for all segments of the U.S. market. These products, along with our flagship product, the ABS2000 (Pending 510(k), not available for sale in the U.S.) and our high volume microtitration plate processing DIAS PLUS system, allow Immucor to offer instrumentation tailored to meet the needs of all clinical laboratory market segments.">>
Immucor is building upon its core technology in the blood market. This strategic alliance may be the final step of securing its market or the necessary technology before approval of the ABS2000.
Regards,
Tom |
